Form 4 Filing by CRISPR Therapeutics AG

Prasad Raju, Chief Financial Officer of CRISPR Therapeutics AG, reported the sale of 3,528 Common Shares on December 22, 2025, for an average price of $55.1022 per share. This transaction was part of a Rule 10b5-1 trading plan. Following this sale, Mr. Raju directly owns 13,239 shares. Additionally, on the same date, Mr. Raju sold 5,472 Common Shares at an average price of $56.3345 per share, also under a Rule 10b5-1 plan, leaving him with 7,767 shares. Further, 1,000 Common Shares were sold at an average price of $56.8858 per share, pursuant to the same trading plan, resulting in 6,767 shares remaining. All sales were executed under a pre-arranged trading plan, with details on specific prices available upon request.